Brief: EQL Pharma Q4 EBITDA Up At SEK 1.1 Mln

EQL Pharma AB

04/05/2020 12:45

May 4 (Reuters) - EQL Pharma AB  EQL.TE :
    * YEAR-END REPORT APRIL 2019 - MARCH 2020
    * WE PRESENT NEW FINANCIAL TARGETS THAT APPLY FOR NEXT
FIVE-YEAR
PERIOD, 2020/21 TO 2024/25, WHERE WE RAISE GROWTH TARGET TO 40
PERCENT ON AVERAGE OVER FIVE-YEAR PERIOD
    * FOR OUR CURRENT FIVE-YEAR PERIOD, CORRESPONDING TARGET IS
MORE
THAN 30 PERCENT GROWTH
    * TARGET FOR OUR EBIT MARGIN IS SET TO BE HIGHER THAN 25
PERCENT
AT END OF NEW FIVE-YEAR PERIOD
    * WE ARE RELATIVELY UNAFFECTED IN SHORT TERMS BY DELIVERY
PROBLEMS
    * ON CORONAVIRUS: COMPANY'S MOVE TO NASDAQ STOCKHOLM'S MAIN
LIST
WILL BE POSTPONED UNTIL Q1 OF FINANCIAL YEAR 2021/22.
    * WE STILL HAVE TO PUT EXTRA ENERGY INTO SECURING SUPPLY FOR
SECOND HALF OF CURRENT FINANCIAL YEAR
    * MOVE TO NASDAQ STOCKHOLM'S MAIN LIST WILL BE POSTPONED
UNTIL Q1
OF FINANCIAL YEAR 2021/22
    * Q4 EBITDA FOR THE QUARTER WAS SEK 1.1 (0.4) MILLION
    * SALES FOR TOTALLED SEK 18.9 MILLION FOR QUARTER, OUR
SECOND
STRONGEST QUARTER EVER, AND SEK 72 MILLION FOR YEAR

Source text for Eikon:  ID:nWkrJfqTM 
Further company coverage:  EQL.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))